Efficacy and safety of ledipasvir/ sofosbuvir for the treatment of chronic hepatitis c in persons with sickle cell disease

Juhi Moon, Robert H. Hyland, Fangqiu Zhang, Diana M. Brainard, Sophie Lanzkron, John G. McHutchison, Mark Sulkowski

Research output: Contribution to journalArticlepeer-review

Abstract

Patients with sickle cell disease are at high risk for chronic hepatitis C infection. Prior treatment has been limited due to the use of ribavirin causing hemolytic anemia and interferon causing cytopenias. We demonstrate the safety and efficacy of fixed-dose combination ledipasvir and sofosbuvir for 12 weeks in this population.

Original languageEnglish (US)
Pages (from-to)864-866
Number of pages3
JournalClinical Infectious Diseases
Volume65
Issue number5
DOIs
StatePublished - Sep 1 2017

Keywords

  • HCV
  • Hepatitis C infection
  • LDV/SOF
  • Ledipasvir
  • Sickle cell disease

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Efficacy and safety of ledipasvir/ sofosbuvir for the treatment of chronic hepatitis c in persons with sickle cell disease'. Together they form a unique fingerprint.

Cite this